Metabolic, Mitochondrial, and Inflammatory Effects of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate in Asymptomatic Antiretroviral-Naïve People with HIV

被引:0
作者
Barroso, Sergio [1 ,2 ,3 ]
Guitart-Mampel, Mariona [1 ,2 ,3 ]
Garcia-Garcia, Francesc Josep [1 ,2 ,3 ]
Canto-Santos, Judith [1 ,2 ,3 ]
Valls-Roca, Laura [1 ,2 ,3 ]
Andujar-Sanchez, Felix [1 ,2 ,3 ]
Vilaseca-Capel, Adria [1 ,2 ,3 ]
Tobias, Ester [1 ,2 ,3 ]
Arias-Dimas, Angela [4 ]
Quesada-Lopez, Tania [5 ,6 ]
Artuch, Rafael [3 ,4 ]
Villarroya, Francesc [5 ,6 ]
Giralt, Marta [5 ,6 ]
Martinez, Esteban [7 ,8 ]
Lozano, Ester [9 ]
Garrabou, Gloria [1 ,2 ,3 ]
机构
[1] Univ Barcelona UB, Cellex Inst Invest Biomed August Pi Sunyer IDIBAPS, Fac Med & Hlth Sci, Inherited Metab Dis & Muscular Disorders Res Lab, Barcelona 08036, Spain
[2] Hosp Clin Barcelona, Dept Internal Med, Barcelona 08036, Spain
[3] Carlos III Hlth Inst, Spanish Biomed Res Ctr Rare Dis, CIBERER, Madrid 28029, Spain
[4] Inst Recerca St Joan Deu, Dept Clin Biochem, Esplugas de Llobregat 08950, Barcelona, Spain
[5] Univ Barcelona UB, Biomed Inst IBUB, Biochem & Mol Biomed Dept, Barcelona 08014, Spain
[6] Carlos III Hlth Inst, CIBER Physiopathol Obes & Nutr CIBEROBN, Madrid 28029, Spain
[7] Hosp Clin Barcelona, Infect Dis Dept, Barcelona 08036, Spain
[8] Carlos III Hlth Inst, CIBER Infect Dis CIBERINFEC, Madrid 28029, Spain
[9] Univ Barcelona UB, Fac Biol, Dept Cell Biol Physiol & Immunol, Barcelona 08028, Spain
关键词
antiretroviral treatment; HIV; metabolic profile; mitochondrial toxicity; mitochondrial DNA; inflammatory effects; tenofovir; emtricitabine; efavirenz; BLOOD MONONUCLEAR-CELLS; ANTIRETROVIRAL THERAPY; LIVER-INJURY; IN-VITRO; TOXICITY; DNA; INFECTION; LIPODYSTROPHY; INHIBITOR; HAART;
D O I
10.3390/ijms25158418
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to comprehensively assess the metabolic, mitochondrial, and inflammatory effects of first-line efavirenz, emtricitabine, and tenofovir disoproxil fumarate (EFV/FTC/TDF) single-tablet regimen (STR) relative to untreated asymptomatic HIV infection. To this end, we analyzed 29 people with HIV (PWH) treated for at least one year with this regimen vs. 33 antiretroviral-na & iuml;ve PWH. Excellent therapeutic activity was accompanied by significant alterations in metabolic parameters. The treatment group showed increased plasmatic levels of glucose, total cholesterol and its fractions (LDL and HDL), triglycerides, and hepatic enzymes (GGT, ALP); conversely, bilirubin levels (total and indirect fraction) decreased in the treated cohort. Mitochondrial performance was preserved overall and treatment administration even promoted the recovery of mitochondrial DNA (mtDNA) content depleted by the virus, although this was not accompanied by the recovery in some of their encoded proteins (since cytochrome c oxidase II was significantly decreased). Inflammatory profile (TNF alpha, IL-6), ameliorated after treatment in accordance with viral reduction and the recovery of TNF alpha levels correlated to mtDNA cell restoration. Thus, although this regimen causes subclinical metabolic alterations, its antiviral and anti-inflammatory properties may be associated with partial improvement in mitochondrial function.
引用
收藏
页数:17
相关论文
共 48 条
[41]   Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV-1-Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis [J].
Behrens, Georg ;
Rijnders, Bart ;
Nelson, Mark ;
Orkin, Chloe ;
Cohen, Calvin ;
Mills, Anthony ;
Elion, Richard A. ;
Vanveggel, Simon ;
Stevens, Marita ;
Rimsky, Laurence ;
Thorpe, David ;
Bosse, Matthew ;
White, Kirsten ;
Zhong, Lijie ;
DeMorin, Jennifer ;
Chuck, Susan K. .
AIDS PATIENT CARE AND STDS, 2014, 28 (04) :168-175
[42]   Treatment of advanced HIV disease in antiretroviral-naive HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine [J].
Uy, Jonathan ;
Yang, Rong ;
Wirtz, Victoria ;
Sheppard, Louise ;
Farajallah, Awny ;
McGrath, Donnie .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2011, 23 (11) :1500-1504
[43]   Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naı<spacing diaeresis>ve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study [J].
Tseng, Yu-Ting ;
Yang, Chia-Jui ;
Kim, Yeon-Sook ;
Choi, Jun Yong ;
Wong, Chen Seong ;
Lee, Kuan-Yeh ;
Lee, Jeong-a ;
Chang, Jack ;
Harrison, Rebecca ;
Marongiu, Andrea ;
Lee, Sun Hee ;
Hung, Chien-Ching .
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2024, 57 (05) :760-770
[44]   Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort [J].
Yokomaku, Yoshiyuki ;
Teruya, Katsuji ;
Watanabe, Dai ;
Endo, Tomoyuki ;
Minami, Rumi ;
Taguchi, Nao ;
Cassidy, Tali ;
Marongiu, Andrea ;
Thorpe, David ;
Shirasaka, Takuma ;
Oka, Shinichi .
PLOS ONE, 2025, 20 (01)
[45]   A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naive patients [J].
Bracchi, Margherita ;
Pagani, Nicole ;
Dalla Pria, Alessia ;
Milinkovic, Ana ;
Nwokolo, Nneka ;
Thomas, Lervina ;
Mandalia, Sundhyia ;
Boffito, Marta ;
Moyle, Graeme .
HIV RESEARCH & CLINICAL PRACTICE, 2021, 22 (05) :128-139
[46]   Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study [J].
Mata Marin, Jose Antonio ;
Velasco-Penagos, Juan Carlos ;
Mauss, Stefan ;
Rodriguez-Evaristo, Mara Soraya ;
Perez-Barragan, Edgar ;
Villa-Platas, Joaquin ;
Barragan-Huerta, Laura ;
Gaytan-Martinez, Jesus Enrique .
INTERNATIONAL JOURNAL OF STD & AIDS, 2024, 35 (01) :33-38
[47]   Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India [J].
Dravid, A. ;
Betha, T. P. ;
Sharma, A. K. ;
Gawali, R. ;
Mahajan, U. ;
Kulkarni, M. ;
Saraf, C. ;
Kore, S. ;
Dravid, M. ;
Rathod, N. .
HIV MEDICINE, 2020, 21 (09) :578-587
[48]   Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial [J].
Maggiolo, Franco ;
Rizzardini, Giuliano ;
Raffi, Francois ;
Pulido, Federico ;
Gracia Mateo-Garcia, Maria ;
Molina, Jean-Michel ;
Ong, Edmund ;
Shao, Yongwu ;
Piontkowsky, David ;
Das, Moupali ;
McNicholl, Ian ;
Haubrich, Richard .
LANCET HIV, 2019, 6 (10) :E655-E666